Има многу работи што прават ремисија и тоа многу лесно, само не е 1 и не е преку ноќ. Најмалце 1 месец треба да помине, и да се елиминира се што е инфламаторна храна.
Турмерикот има докажaн ефект во голем број слепи студии, за многу проблеми - и како за инфо, само нај нај напредните формулации во форма на капсула се по ефикасни од зачинот, левелот на курумин во плазма, нема допирна точка со неговиот ефект, добар дел од него завршува во ткивата/ќелиите, и таму го прави своето силно дејство.
Сум ги тестирал сите можни (добри форми)
Тeracurmin
C3 complex
Longvida
Meriva
BCM95
Зачинот е убедливо нај-ефикасен кога ќе се измеша со маст и црн пипер
http://www.ncbi.nlm.nih.gov/pubmed/21120596
"The present study showed that GTaq (especially the high dose)
was more effective (4.2-38.4% higher, P < 0.05-0.001) than indomethacin (a non-steroidal/anti-inflammatory drug) in alleviating the loss in body weight gain, the histopathological changes observed in ankle joints, blood leukocytosis and thrombocytosis, iron deficiency anemia, serum hypoalbuminemia and globulinemia, the impairment of kidney functions, and the risks for cardiovascular disease in arthritic rats"
http://www.ncbi.nlm.nih.gov/pubmed/25046624
:In a randomised, double-blind, placebo-controlled study, 56 individuals with major depressive disorder were treated with curcumin (500 mg twice daily) or placebo for 8 weeks. The primary measure was the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). Secondary outcomes included IDS-SR30 factor scores and the Spielberger State-Trait Anxiety Inventory (STAI). From baseline to week 4, both curcumin and placebo were associated with improvements in IDS-SR30 total score and most secondary outcome measures.
From weeks 4 to 8, curcumin was significantly more effective than placebo in improving several mood-related symptoms, demonstrated by a significant group x time interaction for IDS-SR30 total score (F1, 53=4.22, p=.045) and IDS-SR30 mood score (F1, 53=6.51, p=.014), and a non-significant trend for STAI trait score (F1, 48=2.86, p=.097). Greater efficacy from curcumin treatment was identified in a subgroup of individuals with atypical depression.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665200/
Her BPSD, including agitation, irritability, and anxiety was not improved, though she was prescribed Yokukansan and atypical antipsychotic drugs. We began to administer turmeric 764 mg/day (curcumin 100 mg/day) to her. She gradually calmed down. Her BPSD, which were hallucination, delusion, depression, agitation, apathy, anxiety, and irritability, were relieved. She stopped urinating outside the front door. She came to put on her clothes properly, and distinguish her family from staffs of the care center. After 12 weeks, judging from the Japanese version of NPI-Q, both acuity of BPSD and burden of caregivers were relieved [Table 2, Figures Figures11 and and2].2]. She has been taking turmeric for more than 1 year; she lives in a peacefully serene manner with her family.
https://www.ncbi.nlm.nih.gov/pubmed/17569213
Тhe specific regulation of 5-LOX and COX-2 by curcumin is not fully established; however, existing evidence indicates that curcumin regulates LOX and COX-2 predominately at the transcriptional level and, to a certain extent, the posttranslational level. Thus, the curcumin-selective transcriptional regulatory action
of COX-2, and dual COX/LOX inhibitory potential of this naturally occurring agent provides distinctive advantages over synthetic COX/LOX inhibitors, such as nonsteroidal anti-inflammatory drugs.
https://www.ncbi.nlm.nih.gov/pubmed/25776839
In this double blind, cross-over trial, 30 obese subjects were randomized to receive either curcumin (1 g/day) or placebo for a period of 30 days. Following a wash-out interval of 2 weeks, each subject was crossed over to the alternative regimen for a further 30 days. Severity of anxiety and depression was assessed at baseline and at weeks 4, 6 and 10 of the trial using the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scales, respectively.
Mean BAI score was found to be significantly reduced following curcumin therapy (P=0.03).
https://www.ncbi.nlm.nih.gov/pubmed/23832433
60 patients diagnosed with MDD were randomized in a 1:1:1 ratio for six weeks observer-masked treatment with fluoxetine (20 mg) and curcumin (1000 mg) individually or their combination. The primary efficacy variable was response rates according to Hamilton Depression Rating Scale, 17-item version (HAM-D17 ). The secondary efficacy variable was the mean change in HAM-D17 score after six weeks. We observed that curcumin was well tolerated by all the patients. The proportion of responders as measured by the HAM-D17 scale was higher in the combination group (77.8%) than in the fluoxetine (64.7%) and the curcumin (62.5%) groups; however, these data were not statistically significant (P = 0.58). Interestingly, the mean change in HAM-D17 score at the end of six weeks was comparable in all three groups (P = 0.77). This study provides first clinical evidence that curcumin may be used as an effective and safe modality for treatment in patients with MDD without concurrent suicidal ideation or other psychotic disorders. .
И уште еден тон видеа, турмерикот е чудо од билка.